AAPL   270.61 (-1.06%)
FB   189.11 (-0.34%)
MSFT   160.93 (+1.74%)
GOOGL   1,305.10 (-0.75%)
AMZN   1,858.23 (-1.38%)
CGC   18.31 (-0.71%)
NVDA   264.32 (+4.64%)
BABA   203.89 (-0.56%)
GE   10.52 (+1.15%)
TSLA   652.64 (-3.88%)
AMD   44.75 (+1.68%)
T   35.12 (-1.71%)
F   6.88 (-1.29%)
BAC   28.27 (-2.95%)
GILD   68.54 (-5.67%)
AAPL   270.61 (-1.06%)
FB   189.11 (-0.34%)
MSFT   160.93 (+1.74%)
GOOGL   1,305.10 (-0.75%)
AMZN   1,858.23 (-1.38%)
CGC   18.31 (-0.71%)
NVDA   264.32 (+4.64%)
BABA   203.89 (-0.56%)
GE   10.52 (+1.15%)
TSLA   652.64 (-3.88%)
AMD   44.75 (+1.68%)
T   35.12 (-1.71%)
F   6.88 (-1.29%)
BAC   28.27 (-2.95%)
GILD   68.54 (-5.67%)
AAPL   270.61 (-1.06%)
FB   189.11 (-0.34%)
MSFT   160.93 (+1.74%)
GOOGL   1,305.10 (-0.75%)
AMZN   1,858.23 (-1.38%)
CGC   18.31 (-0.71%)
NVDA   264.32 (+4.64%)
BABA   203.89 (-0.56%)
GE   10.52 (+1.15%)
TSLA   652.64 (-3.88%)
AMD   44.75 (+1.68%)
T   35.12 (-1.71%)
F   6.88 (-1.29%)
BAC   28.27 (-2.95%)
GILD   68.54 (-5.67%)
AAPL   270.61 (-1.06%)
FB   189.11 (-0.34%)
MSFT   160.93 (+1.74%)
GOOGL   1,305.10 (-0.75%)
AMZN   1,858.23 (-1.38%)
CGC   18.31 (-0.71%)
NVDA   264.32 (+4.64%)
BABA   203.89 (-0.56%)
GE   10.52 (+1.15%)
TSLA   652.64 (-3.88%)
AMD   44.75 (+1.68%)
T   35.12 (-1.71%)
F   6.88 (-1.29%)
BAC   28.27 (-2.95%)
GILD   68.54 (-5.67%)
Log in

OTCMKTS:NSPX - Inspyr Therapeutics Stock Price, Forecast & News

$0.0022
0.00 (0.00 %)
(As of 02/28/2020 02:48 PM ET)
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.20
Volume571,705 shs
Average Volume3.53 million shs
Market Capitalization$25,036.00
P/E RatioN/A
Dividend YieldN/A
Beta0.6
Inspyr Therapeutics, Inc., an early-stage pharmaceutical company, focuses on the discovery and development of prodrug cancer therapeutics in the United States. It develops cancer therapeutics for the treatment of solid tumors, including brain, liver, prostate, and other cancers. The company's lead drug candidate is mipsagargin, which has completed an open label single arm Phase II clinical trial in patients with advanced hepatocellular carcinoma or liver cancer. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was founded in 2003 and is based in Westlake Village, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:NSPX
CUSIPN/A
CIKN/A
Phone818-661-6302

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($21.58) per share

Profitability

Net Income$-10,000.00

Miscellaneous

Employees7
Market Cap$25,036.00
Next Earnings DateN/A
OptionableNot Optionable

Receive NSPX News and Ratings via Email

Sign-up to receive the latest news and ratings for NSPX and its competitors with MarketBeat's FREE daily newsletter.


Inspyr Therapeutics (OTCMKTS:NSPX) Frequently Asked Questions

What is Inspyr Therapeutics' stock symbol?

Inspyr Therapeutics trades on the OTCMKTS under the ticker symbol "NSPX."

How were Inspyr Therapeutics' earnings last quarter?

Inspyr Therapeutics Inc (OTCMKTS:NSPX) announced its earnings results on Monday, August, 14th. The company reported ($0.35) earnings per share (EPS) for the quarter. View Inspyr Therapeutics' Earnings History.

Has Inspyr Therapeutics been receiving favorable news coverage?

News coverage about NSPX stock has trended very negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Inspyr Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Inspyr Therapeutics.

Who are some of Inspyr Therapeutics' key competitors?

What other stocks do shareholders of Inspyr Therapeutics own?

Who are Inspyr Therapeutics' key executives?

Inspyr Therapeutics' management team includes the folowing people:
  • Mr. Christopher P. Lowe, CEO, CFO, Pres, Principal Accounting Officer & Exec. Director (Age 48)
  • Dr. John T. Isaacs, Co-Founder, Chairman of Scientific Advisory Board & Chief Scientific Advisor
  • Dr. Samuel R. Denmeade, Co-Founder, Chief Clinical Advisor and Member of Scientific Advisory Board

How do I buy shares of Inspyr Therapeutics?

Shares of NSPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Inspyr Therapeutics' stock price today?

One share of NSPX stock can currently be purchased for approximately $0.00.

How big of a company is Inspyr Therapeutics?

Inspyr Therapeutics has a market capitalization of $25,036.00. Inspyr Therapeutics employs 7 workers across the globe.View Additional Information About Inspyr Therapeutics.

What is Inspyr Therapeutics' official website?

The official website for Inspyr Therapeutics is http://www.genspera.com/.

How can I contact Inspyr Therapeutics?

Inspyr Therapeutics' mailing address is 31200 VIA COLINAS SUITE 200, WESTLAKE VILLAGE CA, 91362. The company can be reached via phone at 818-661-6302 or via email at [email protected]


MarketBeat Community Rating for Inspyr Therapeutics (OTCMKTS NSPX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  69 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  147
MarketBeat's community ratings are surveys of what our community members think about Inspyr Therapeutics and other stocks. Vote "Outperform" if you believe NSPX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NSPX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel